EFG Asset Management North America Corp. Lowers Stake in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• EFG Asset Management North America Corp. reduced its stake in Ultragenyx Pharmaceutical by 11.8%, resulting in ownership of 122,942 shares worth approximately $4.45 million.
• Several institutional investors have also modified their positions, with notable increases from GAMMA Investing LLC and California State Teachers Retirement System in the first quarter.
• Ultragenyx Pharmaceutical's stock has experienced a 1.5% decrease recently, and analysts have average price targets ranging from $34.00 to $136.00, with a consensus price target of $81.50.

EFG Asset Management North America Corp. trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 11.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 122,942 shares of the biopharmaceutical company's stock after selling 16,501 shares during the period. EFG Asset Management North America Corp. owned about 0.13% of Ultragenyx Pharmaceutical worth $4,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in RARE. California State Teachers Retirement System boosted its holdings in shares of Ultragenyx Pharmaceutical by 0.3% in the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock valued at $3,284,000 after purchasing an additional 268 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares during the period. Xponance Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.8% in the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock worth $455,000 after buying an additional 347 shares during the period. BOKF NA lifted its holdings in shares of Ultragenyx Pharmaceutical by 5.0% in the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after buying an additional 382 shares during the period. Finally, Oak Ridge Investments LLC lifted its stake in Ultragenyx Pharmaceutical by 2.3% in the first quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock worth $643,000 after acquiring an additional 395 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares in the company, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Stock Down 1.5%

Shares of Ultragenyx Pharmaceutical stock opened at $31.55 on Thursday. The firm has a market capitalization of $3.04 billion, a P/E ratio of -5.71 and a beta of 0.21. The company has a 50 day moving average price of $30.61 and a 200 day moving average price of $35.02. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. During the same quarter last year, the company posted ($1.52) earnings per share. The business's quarterly revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on RARE shares. Guggenheim reaffirmed a "buy" rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Wedbush lowered their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. HC Wainwright upgraded Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price for the company in a report on Monday, July 28th. Canaccord Genuity Group lowered their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, William Blair started coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Eleven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.